CHICAGO — an investigational drug for influenza that targets a host-cell factor necessary for infection reduced viral loads by more than 100-fold in a randomized trial, a researcher said here. an inhalable fusion protein called DAS181 reduced viral loads by 2.38 log10 relative to placebo on day five after symptom onset in the 297-patient trial (P=0.008), according to Roy Steigbigel, MD, of the State University of New York at Stony Brook. three days of once-daily treatment led to decreases in viral loads of 1.01 log10 on day two and 1.46 log10 on day three relative to placebo (both P<0.01), Steigbigel told attendees at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Action Points  

• Note that this study was published as an abstract and presented at a conference. these data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
• Explain that an investigational drug for influenza that targets a host-cell factor necessary for infection reduced viral loads by more than 100-fold in a randomized trial.
• Note that the drug studied, an inhalable fusion protein called DAS181, targets sialic acid, a receptor on airway cells to which the flu virus’s hemagglutinin protein binds.

However, elevations of alkaline phosphatase were seen in most patients receiving the drug but only rarely in the placebo group, Steigbigel said. the same signal was seen in preclinical studies with DAS181 and is apparently the result of systemic exposure to the drug, causing reduced clearance of the enzyme.

DAS181 targets sialic acid, a receptor on airway cells to which the flu virus’s hemagglutinin protein binds. This is the process that allows the virus to enter host cells and begin replicating.

The drug combines a sialidase enzyme molecule with an anchor protein attaching the drug to cell surfaces so that its effect is prolonged.

Steigbigel reported results from an international phase II trial conducted across three flu seasons in the northern and southern hemispheres.

Patients were 18 to 68 years old and were enrolled within 48 hours of symptom onset, with confirmation of flu infection by a standard rapid test.

They were assigned to three double-blind treatment groups: three doses of placebo; DAS181 given as a single 10-mg dose on the first day, followed by two daily placebo doses; or three daily doses of 10 mg DAS181.

Excluding patients who didn’t receive the assigned doses, there were 88 patients in each group.

The single dose of DAS181 was only slightly more effective than placebo for the major study endpoints, which included time to decreased viral shedding as well as viral loads in gargle washes.

But the three-dose regimen was significantly superior to placebo for both endpoints.

Decreased viral shedding was assessed as the time from baseline to a 1-log10 decrease in viral burden in gargle washes. among patients receiving three daily doses of DAS181, it was achieved in a median of two days, compared with four days for the placebo group.

Steigbigel said the study was not powered for clinical efficacy endpoints, and he did not report on whether the drug shortened time with symptoms.

He did indicate, though, that use of acetaminophen for symptom relief was more frequent in the placebo group.

Session co-moderator Laurent Kaiser, MD, of the University Hospital of Geneva in Switzerland, questioned whether the deactivation of sialic acid receptors could create increased opportunities for bacterial infection.

Some research had suggested that pneumococcal bacteria might be better able to infect airway tissue in the absence of sialic acid.

Steigbigel responded this had been a concern with DAS181 and was examined in animal studies, which found no evidence of increased susceptibility to such infections.

“The proof of the pudding will be in the clinical data,” he added. the phase I and phase II studies had so far not revealed any increased risk, Steigbigel said.

At a separate press briefing, Kaiser said DAS181 was one of several promising new anti-flu agents in the development pipeline.

He noted that, currently, the only drugs specific for flu are inhibitors of the virus’s neuraminidase enzyme.

“We will have soon, hopefully, other drugs than the neuraminidase inhibitors to target influenza and to open the possibility of combined therapy for severe cases,” Kaiser said.

The study was funded by the National Institute of Allergy and Infectious Diseases. DAS181 is under development by NexBio.

Steigbigel declared he had no relevant financial interests. all other investigators on the study were NexBio employees.

sorry its such a long question :I i jusrt wanted to know, because my grandmother is bedridden with ms, and has been for about 40years (she is 56), she is in hospital at the moment in ICU, she nearly died, id go into detail but yeah, really appreciate real answers, thanks (: xx (oh and im 13, lol )

"a small number of patients have malignant MS, which is marked by a rapid decline that leads to disability and possibly death. MS is rarely fatal, however, and most people with the disease have a normal life expectancy." ( Ed Zimney MD, Health Talk Medical Reference.)

You can die from some of the complications arising from having MS – usually respiratory distress or pneumonia. one study states that: "Median observed survival time was 38.0 years from symptom onset."

"the simple, profit-free truth is: a healthy diet can stop this disease. a hard look at the evidence will lead all but the "financially tainted" to the conclusion that the time has long passed to change the way people with MS are treated."

Stop MS>>>
drmcdougall.com/stars/050812t…

Reverse it: My Experience with MS>>>
youtube.com/watch?v=35v7UFpBP…

Reversing MS – amazing healing>>>
youtube.com/watch?v=HlXXg49vz…

Healed from MS and psorasis>>>
youtube.com/watch?v=ZFhjBmENT…

Maddy, you poor thing. I feel for you and your family. My daughter is 18 now, but was about 7 or 8 when I was diagnosed. Thank the Lord I'm functioning and walking. There is no timetable for MS. its a very individual disease. unfortunately that's as real an answer you're gonna get. I'm sorry you're going through this, but as with any illness, enjoy the people you love for as long as you have them with you. Stay strong.

Hi, Maddy,

MS is an illness that is often compared to a roller coaster. People can have very serious symptoms and then go back to feeling better.

Many people with MS have been diagnosed with CCSVI (Chronic Cerebral Spinal Venous Insufficiency) which means that they have a thickening in their veins where the blood drains from the brain. Veins take the cellular waste away from the brain. When they are thick or blocked, they don't do a good job removing the wastes and a buildup of iron or other unneeded elements sits in the brain and can add to the difficult physical symptoms of MS.

A doctor in Italy named Dr Zamboni (yes, just like the machine that smooths the ice before hockey games), found these blockages and came up with a way to open the veins so that the blood can drain more freely. here is some more information: sanoviv.com/medical-services/ccsv… and en.wikipedia.org/wiki/Chronic_cer…

It would be good if you shared this information with your parents, or your grandmother when she is feeling better. That way you can be part of the team that is dedicated to your grandmother's improved health.

Wishing you and your grandmother a healthy and happy year.

Sorry about your grandma. MS itself is not fatal. usually the complications brought about by the illness are responsible for the death of a person with MS. these complications can range from bed sores getting to something much worse to liver and other internal organ problems.

I am not a doctor but as a person with MS for the past 14 years I can assure you MS is not terminal.

Take care and be well,

Alex